Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, ...

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

Flow's FL-100 device is expected to be available in the US as soon as Q2 2026. Image credit: Tada Images via Shutterstock.com. The US Food and Drug Administration (FDA) has cleared Flow Neuroscience’s ...

A large twin study found that adverse childhood experiences increase the risk of developing treatment-resistant depression.

– Successful outcome from recent FDA meeting guides Alto’s plan to accelerate development of ALTO-207, with capital from a $50 million private placement financing expected to enable the company to ...

– Issued and pending claims expected to protect ALTO-207 into the mid-2040s – MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical ...

Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto Neuroscience announced positive pharmacodynamic results from an exploratory ...

Rates of depression and stress-related disorders rise among new fathers a year after birth, even though they have fewer mental health diagnoses during pregnancy and the first few months after birth.

– Issued and pending claims expected to protect ALTO-207 into the mid-2040s – The company believes that, together with previously issued patents and pending applications in the U.S. and ...